Latest Content

A phase 3 trial update for GLSI-100 shows a recurrence rate of less than 1% per year in patients with HER2-positive breast cancer after immunization.

At CURE, we strive to provide insight, education and inspiration for patients, survivors and caregivers at every stage of the cancer journey.

Survivor Casey Liening discusses her metastatic breast cancer journey, reaching NED, and why a stage 4 diagnosis is a beginning, not a death sentence.

Dr. Jennifer Amengual explains how epigenetic therapies treat lymphomas by changing gene expression rather than killing dividing cells like chemotherapy.

Personalized treatment, exercise and supportive care improve outcomes for patients with metastatic hormone-sensitive prostate cancer.

Dr. Don S. Dizon presented information on pregnancy with a breast cancer diagnosis and what patients should know.

Studies show Signatera ctDNA testing may predict recurrence and guide treatment decisions in anal and rectal cancers.

The CAPTAIN trial shows MRI-guided TULSA preserved erectile and urinary function versus surgery in localized prostate cancer.

A daughter’s cancer journey shows that survivorship is filled with constant waiting—from tests and treatment to life milestones — where each result can bring relief or fear.

Stage 1 mixed cellularity Hodgkin lymphoma is often highly treatable with chemotherapy and radiation, with additional therapies available if the disease returns.

A colorectal cancer survivor shares what life with an ostomy is really like, offering advice and reassurance for patients adjusting after surgery.

CURE was live on site at the the 19th Annual New York GU Cancers Congress®, where we spoke with Dr. Ulka Vaishampayan on the topic of kidney cancer.

Dr. Anastasia Tousimis explores the feasibility, risks and surgical techniques for performing NSM in radiated patients to ensure oncologic safety.